Epizyme Switches CEOs as Synageva’s Bazemore Steps in For Gould

Xconomy Boston — 

Robert Gould, who has led Epizyme (NASDAQ: EPZM) for more than five years—from a venture-backed startup to a publicly traded entity—is stepping down as CEO of the Cambridge, MA-based company. Epizyme has named former Synageva Pharmaceuticals chief operating officer Robert Bazemore its new CEO, effective Sept. 10. Gould, a former Merck executive who has been an Epizyme boardmember since its inception seven years ago, will stay on Epizyme’s board following the transition and serve as a consultant. Synageva, meanwhile, was bought by Alexion Pharmaceuticals earlier this year for $8.4 billion.